{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:57Z","timestamp":1791357357865,"version":"4.3.1"},"reference-count":79,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1001\/jamapediatrics.2019.0905","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:01:12Z","timestamp":1559055672000},"page":"630","source":"Crossref","is-referenced-by-count":67,"title":["Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1001","volume":"173","author":[{"given":"Cellina","family":"Ching","sequence":"first","affiliation":[{"name":"Western Sydney University, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy D.","family":"Eslick","sequence":"additional","affiliation":[{"name":"The Whiteley-Martin Research Centre, Department of Surgery, The University of Sydney, Penrith, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison S.","family":"Poulton","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre Nepean, The University of Sydney, Penrith, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"poi190018r1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00406-011-0211-9","article-title":"The estimated prevalence and correlates of adult ADHD in a German community sample.","volume":"262","author":"de Zwaan","year":"2012","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"poi190018r2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s13311-012-0135-8","article-title":"The prevalence of DSM-IV attention-deficit\/hyperactivity disorder: a meta-analytic review.","volume":"9","author":"Willcutt","year":"2012","journal-title":"Neurotherapeutics"},{"issue":"5","key":"poi190018r3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jaac.2018.02.012","article-title":"Has the prevalence of child and adolescent mental disorders in Australia changed between 1998 and 2013 to 2014?","volume":"57","author":"Sawyer","year":"2018","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"poi190018r5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4088\/JCP.11m07529","article-title":"Adult outcome of attention-deficit\/hyperactivity disorder: a controlled 16-year follow-up study.","volume":"73","author":"Biederman","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"poi190018r6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2165\/00148581-200305120-00006","article-title":"Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.","volume":"5","author":"Biederman","year":"2003","journal-title":"Paediatr Drugs"},{"issue":"2","key":"poi190018r7","doi-asserted-by":"publisher","first-page":"e0116407","DOI":"10.1371\/journal.pone.0116407","article-title":"Effect of treatment modality on long-term outcomes in attention-deficit\/hyperactivity disorder: a systematic review.","volume":"10","author":"Arnold","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"poi190018r8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1542\/peds.2011-1761","article-title":"ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents.","volume":"128","author":"Subcommittee on Attention-Deficit\/Hyperactivity Disorder Steering Committee on Quality Improvement and Management","year":"2011","journal-title":"Pediatrics"},{"issue":"6","key":"poi190018r9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/00004583-199706000-00011","article-title":"Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate.","volume":"36","author":"Schachar","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"poi190018r10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1542\/peds.100.4.662","article-title":"Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.","volume":"100","author":"Efron","year":"1997","journal-title":"Pediatrics"},{"issue":"3","key":"poi190018r11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2165\/00023210-200822030-00003","article-title":"Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.","volume":"22","author":"Graham","year":"2008","journal-title":"CNS Drugs"},{"key":"poi190018r12","doi-asserted-by":"publisher","first-page":"I7","DOI":"10.1007\/s00787-004-1002-x","article-title":"European Clinical Guidelines for Hyperkinetic Disorder\u2013first upgrade.","volume":"13","author":"Taylor","year":"2004","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"4","key":"poi190018r17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement.","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"11","key":"poi190018r18","first-page":"CD009885","article-title":"Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).","author":"Storeb\u00f8","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"poi190018r25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"poi190018r26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"poi190018r27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"poi190018r28","first-page":"157","article-title":"A fail-safe N for effect size in meta-analysis.","volume":"8","author":"Orwin","year":"1983","journal-title":"J Educ Stat"},{"issue":"4","key":"poi190018r29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1089\/cap.2004.14.542","article-title":"A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.","volume":"14","author":"Arnold","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"poi190018r30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4088\/JCP.v69n0120","article-title":"A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit\/hyperactivity disorder.","volume":"69","author":"Findling","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"poi190018r31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s00787-006-0565-0","article-title":"Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention deficit\/hyperactivity disorder.","volume":"15","author":"Findling","year":"2006","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"poi190018r32","doi-asserted-by":"publisher","first-page":"E39","DOI":"10.1542\/peds.109.3.e39","article-title":"A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit\/hyperactivity disorder.","volume":"109","author":"Greenhill","year":"2002","journal-title":"Pediatrics"},{"issue":"8","key":"poi190018r33","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/00004583-199908000-00009","article-title":"Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?","volume":"38","author":"Law","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"poi190018r34","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jaac.2011.06.010","article-title":"Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit\/hyperactivity disorder and substance use disorders.","volume":"50","author":"Riggs","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"poi190018r35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/jcpp.2013.54.issue-5","article-title":"Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.","volume":"54","author":"Simonoff","year":"2013","journal-title":"J Child Psychol Psychiatry"},{"issue":"1","key":"poi190018r36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archpedi.160.1.82","article-title":"Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit\/hyperactivity disorder.","volume":"160","author":"Wilens","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"poi190018r37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1542\/peds.108.4.883","article-title":"Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit\/hyperactivity disorder.","volume":"108","author":"Wolraich","year":"2001","journal-title":"Pediatrics"},{"issue":"3","key":"poi190018r38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5455\/bcp.20150802050349","article-title":"Plasma norepinephrine and dopamine levels in prepubertal male children with attention-deficit hyperactivity disorder do not change with 8 weeks of methylphenidate treatment.","volume":"25","author":"Alsen","year":"2015","journal-title":"Klinik Psikofarmakol B\u00fclteni"},{"issue":"1","key":"poi190018r39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1185\/03007990903437412","article-title":"Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit\/hyperactivity disorder symptom control and tolerability after abrupt conversion.","volume":"26","author":"Arnold","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"poi190018r40","doi-asserted-by":"publisher","first-page":"e796","DOI":"10.1542\/peds.2010-0086","article-title":"Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD.","volume":"126","author":"Blader","year":"2010","journal-title":"Pediatrics"},{"issue":"3","key":"poi190018r41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/00004703-198109000-00003","article-title":"Optimal dosages of methylphenidate for improving the learning and behavior of hyperactive children.","volume":"2","author":"Charles","year":"1981","journal-title":"J Dev Behav Pediatr"},{"issue":"1","key":"poi190018r42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/cap.2016.0002","article-title":"Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6-12 years of age with attention-deficit\/hyperactivity disorder in the laboratory classroom setting.","volume":"27","author":"Childress","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"poi190018r43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/0269881111405356","article-title":"Norepinephrine transporter -3081(A\/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.","volume":"26","author":"Cho","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"3","key":"poi190018r44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/cap.2011.0006","article-title":"Remission in children and adolescents diagnosed with attention-deficit\/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.","volume":"22","author":"Chou","year":"2012","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"poi190018r45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/000992280003900102","article-title":"A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder.","volume":"39","author":"Connor","year":"2000","journal-title":"Clin Pediatr (Phila)"},{"issue":"8","key":"poi190018r46","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/01.chi.0000166986.30592.67","article-title":"Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation.","volume":"44","author":"Correia Filho","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"poi190018r47","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/cap.2009.0122","article-title":"A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit\/hyperactivity disorder.","volume":"20","author":"Findling","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"poi190018r48","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.clinthera.2009.08.002","article-title":"Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit\/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.","volume":"31","author":"Findling","year":"2009","journal-title":"Clin Ther"},{"issue":"1","key":"poi190018r49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0002-7138(09)60723-8","article-title":"Differential effects of parent training and stimulant medication with hyperactives: a progress report.","volume":"20","author":"Firestone","year":"1981","journal-title":"J Am Acad Child Psychiatry"},{"issue":"6","key":"poi190018r50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00787-005-0486-3","article-title":"12-Month efficacy and safety of OROS MPH in children and adolescents with attention-deficit\/hyperactivity disorder switched from MPH.","volume":"14","author":"Hoare","year":"2005","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"5","key":"poi190018r51","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/BF02849870","article-title":"Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.","volume":"22","author":"Kemner","year":"2005","journal-title":"Adv Ther"},{"issue":"4","key":"poi190018r52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/JCP.0b013e3182905a8d","article-title":"ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.","volume":"33","author":"Kim","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"poi190018r53","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1089\/cap.2016.0186","article-title":"Effectiveness and side effect profile of stimulant medication for the treatment of attention-deficit\/hyperactivity disorder in youth with epilepsy.","volume":"27","author":"Kral","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"poi190018r54","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1089\/cap.2006.0012","article-title":"Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct\/oppositional-defiant disorder, and aggression: a prospective, open-label study.","volume":"17","author":"Kronenberger","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"poi190018r55","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics: a randomized controlled trial.","volume":"58","author":"Kurlan","year":"2002","journal-title":"Neurology"},{"issue":"8","key":"poi190018r56","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jaac.2016.04.020","article-title":"Effects of d-methylphenidate, guanfacine, and their combination on electroencephalogram resting state spectral power in attention-deficit\/hyperactivity disorder.","volume":"55","author":"Loo","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"poi190018r57","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/cap.2008.053","article-title":"The open-label treatment of attention-deficit\/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate.","volume":"19","author":"Maayan","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"poi190018r58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/cap.2006.16.351","article-title":"Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit\/hyperactivity disorder.","volume":"16","author":"McGough","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"poi190018r59","first-page":"184","article-title":"Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit\/hyperactivity disorder: an open-label study.","volume":"28","author":"Na","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"poi190018r60","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1176\/appi.ajp.2007.05091676","article-title":"Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.","volume":"165","author":"Newcorn","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"3","key":"poi190018r61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/cap.2009.0102","article-title":"Dose-response characteristics in adolescents with attention-deficit\/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study.","volume":"20","author":"Newcorn","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"poi190018r62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/chi.0b013e31815d9af7","article-title":"Clonidine for attention-deficit\/hyperactivity disorder: I. efficacy and tolerability outcomes.","volume":"47","author":"Palumbo","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"poi190018r63","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.comppsych.2009.08.004","article-title":"Temperament and character dimensions associated with clinical characteristics and treatment outcome in attention-deficit\/hyperactivity disorder boys.","volume":"51","author":"Purper-Ouakil","year":"2010","journal-title":"Compr Psychiatry"},{"key":"poi190018r64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.yebeh.2015.02.019","article-title":"Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies.","volume":"46","author":"Radziuk","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"10","key":"poi190018r65","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1089\/cap.2015.0264","article-title":"Acute and long-term cardiovascular effects of stimulant, guanfacine, and combination therapy for attention-deficit\/hyperactivity disorder.","volume":"26","author":"Sayer","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"poi190018r66","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4306\/pi.2012.9.3.257","article-title":"Titrating optimal dose of osmotic-controlled release oral delivery (OROS)-methylphenidate and its efficacy and safety in Korean children with ADHD: a multisite open labeled study.","volume":"9","author":"Song","year":"2012","journal-title":"Psychiatry Investig"},{"issue":"9","key":"poi190018r67","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40263-013-0086-6","article-title":"A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.","volume":"27","author":"Soutullo","year":"2013","journal-title":"CNS Drugs"},{"issue":"5","key":"poi190018r68","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/JCP.0000000000000389","article-title":"Remission rate and functional outcomes during a 6-month treatment with osmotic-release oral-system methylphenidate in children with attention-deficit\/hyperactivity disorder.","volume":"35","author":"Su","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"poi190018r69","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1089\/cap.2015.0031","article-title":"Osmotic release oral system methylphenidate versus atomoxetine for the treatment of attention-deficit\/hyperactivity disorder in Chinese youth: 8-week comparative efficacy and 1-year follow-up.","volume":"26","author":"Su","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1-2","key":"poi190018r70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mrgentox.2009.05.005","article-title":"Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder.","volume":"677","author":"Tucker","year":"2009","journal-title":"Mutat Res"},{"issue":"3","key":"poi190018r71","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/00048670601057767","article-title":"Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.","volume":"41","author":"Wang","year":"2007","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"poi190018r72","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40263-015-0241-3","article-title":"Efficacy of methylphenidate hydrochloride extended-release capsules (Aptensio XR\u2122) in children and adolescents with attention-deficit\/hyperactivity disorder: a phase III, randomized, double-blind study.","volume":"29","author":"Wigal","year":"2015","journal-title":"CNS Drugs"},{"issue":"4","key":"poi190018r73","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/01.CHI.0000046814.95464.7D","article-title":"ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.","volume":"42","author":"Wilens","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"poi190018r74","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/CHI.0b013e31816bffdf","article-title":"Varying the wear time of the methylphenidate transdermal system in children with attention-deficit\/hyperactivity disorder.","volume":"47","author":"Wilens","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"poi190018r75","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00787-016-0902-x","article-title":"An RCT into the effects of neurofeedback on neurocognitive functioning compared to stimulant medication and physical activity in children with ADHD.","volume":"26","author":"Gelad\u00e9","year":"2017","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"4","key":"poi190018r76","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1542\/peds.84.4.648","article-title":"Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children.","volume":"84","author":"Tannock","year":"1989","journal-title":"Pediatrics"},{"issue":"2","key":"poi190018r77","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00004583-199103000-00011","article-title":"Additive effects of psychostimulants, parent training, and self-control therapy with ADHD children.","volume":"30","author":"Horn","year":"1991","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"poi190018r78","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/cap.1993.3.81","article-title":"Childhood hyperactivity and psychostimulants: a review of extended treatment studies.","volume":"3","author":"Schachar","year":"1993","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"poi190018r79","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1542\/peds.112.5.e404","article-title":"A dose-response study of OROS methylphenidate in children with attention-deficit\/hyperactivity disorder.","volume":"112","author":"Stein","year":"2003","journal-title":"Pediatrics"},{"key":"poi190018r4","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"poi190018r16","volume-title":"Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists. Methylphenidate. Australian Medicines Handbook","author":"The Royal Australian College of General Practitioners","year":"2016"},{"key":"poi190018r19","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American Psychiatric Association","year":"1980","edition":"3rd ed"},{"key":"poi190018r20","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American Psychiatric Association","year":"1987","edition":"3rd ed, revised"},{"key":"poi190018r21","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American Psychiatric Association","year":"1994","edition":"4th ed"},{"key":"poi190018r22","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American Psychiatric Association","year":"2000","edition":"4th ed, text re"},{"key":"poi190018r23","volume-title":"International Classification of Diseases, Ninth Revision (ICD-9).","author":"World Health Organization","year":"1977"},{"key":"poi190018r24","volume-title":"International Statistical Classification of Diseases, Tenth Revision (ICD-10)","author":"World Health Organization","year":"1992"},{"key":"poi190018r13","unstructured":"CONCERTA (methylphenidate HCl) extended-release tablets CII. Food and Drug Administration. 2007. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021121s014lbl.pdf. Accessed November 8, 2016."},{"key":"poi190018r14","unstructured":"Ritalin hydrochloride methylphenidate hydrochloride tablets USP. Food and Drug Administration. 2007. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/010187s069,018029s040,021284s011lbl.pdf. Accessed November 14, 2016."},{"key":"poi190018r15","unstructured":"eTG Complete. Attention deficit hyperactivity disorder. Therapeutic Guidelines Limited. http:\/\/online.tg.org.au. Accessed November 14, 2016."}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamapediatrics\/article-pdf\/173\/7\/630\/17691990\/jamapediatrics_ching_2019_oi_190018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T19:19:48Z","timestamp":1663528788000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpedi.jamanetwork.com\/article.aspx?doi=10.1001\/jamapediatrics.2019.0905"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2019.0905","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,1]]}}}